Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a ...

FY 2025 Financial Results and Strengthened Liquidity Position - MAIA Biotechnology reported financial results for the year ended December 31, 2025, reflecting continued investment in clinical ...

MIT Technology Review discovered that the stealth startup’s founder John Schloendorn also pitched a startling, medically ...

Profusa (PFSA) shares jumped 173% following announcement of $30M equity deal to acquire PanOmics diagnostics platform from BioInsights LLC.

After being knocked back in 2024, serial biotech acquirer Kevin Tang has used a different route to finally get his hands on Kezar Life Sciences.   | Autoimmune specialist Aurinia, which named Kevin ...

Canaccord Genuity continues to see meaningful upside in Aroa Biosurgery, as sweeping US reimbursement reforms create a more ...

I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.

Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it ...

Eli Lilly has won FDA approval for its oral obesity drug Foundayo™ (orforglipron), but the stock bounce was short lived as ...

Lilly has signed a deal with AI drug developer Insilico that’s worth $115 million up front and approximately $2.75 billion in biobucks ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...